Skip to main content

Table 1 Characteristics of AECOPD patients with and without CAP

From: The association of delta neutrophil index with the prognosis of acute exacerbation of chronic obstructive pulmonary disease

Characteristics

AECOPD with CAP

P-value

AECOPD without CAP

P-value

Readmission

≤ 30 days

(n = 19)

Readmission

>  30 days

(n = 121)

Readmission

≤ 30 days

(n = 22)

Readmission

>  30 days

(n = 152)

Age, y, mean (SD)

76.2 ± 7.4

72.1 ± 8.7

0.055

72.8 ± 11.1

71.8 ± 9.8

0.655

Male sex, n (%)

14 (73.7)

93 (76.9)

0.627

15 (68.2)

118 (77.6)

0.329

CAT score, mean (SD)

25.4 ± 6.8

22.7 ± 6.7

0.107

25.2 ± 5.9

22.0 ± 7.2

0.044

amMRC dyspnea scale, n (%)

 2–4

15 (78.9)

96 (79.3)

0.869

18 (81.8)

117 (77.0)

0.787

 GOLD stage, A/B/C/D, n

1/7/3/8

2/54/23/42

0.332

0/9/4/9

5/83/24/40

0.095

 GOLD C, D ratio, n (%)

11 (57.9)

65 (53.7)

0.379

13 (59.1)

64 (42.1)

0.134

 Long-term oxygen therapy

7 (36.8)

26 (21.5)

0.117

6 (9.1)

27 (17.8)

0.380

 Smoking amount, py, mean (SD)

43.1 ± 17.4

40.3 ± 15.8

0.506

45.0 ± 13.4

42.7 ± 17.8

0.604

 BMI, kg/m2

21.9 ± 2.6

21.3 ± 2.9

0.481

21.5 ± 2.8

21.9 ± 3.8

0.666

Underlying comorbid conditions, n (%)

 Hypertension

7 (36.8)

71 (58.7)

0.140

15 (68.2)

103 (67.8)

0.969

 Diabetes mellitus

12 (63.2)

59 (48.8)

0.190

8 (36.4)

71 (46.7)

0.362

 Congestive heart failure

5 (26.3)

33 (27.3)

0.855

8 (36.4)

56 (36.8)

0.965

 Chronic kidney disease

1 (5.3)

5 (4.1)

0.726

1 (4.5)

3 (2.0)

0.421

 Hepatobiliary disease

0 (0.0)

3 (2.5)

0.306

1 (4.5)

3 (2.0)

0.421

Medications before an admission, n (%)

 Inhaled corticosteroids

11 (57.9)

72 (59.5)

0.951

13 (59.1)

86 (56.6)

0.824

 Long-acting muscarinic antagonists

10 (52.6)

69 (57.0)

0.598

12 (54.5

76 (50.0)

0.690

 Long-acting beta2 agonists

11 (57.9)

62 (51.2)

0.943

9 (40.9)

83 (54.6)

0.229

Functional parameters, %, mean (SD)

 Post-bronchodilator FEV1/FVC

49.0 ± 10.3

49.45 ± 13.6

0.962

48.3 ± 13.8

52.7 ± 13.2

0.093

 Post-bronchodilator FEV1

58.7 ± 23.9

54.6 ± 21.0

0.606

55.5 ± 29.8

60.7 ± 22.5

0.217

 Post-bronchodilator FVC

78.8 ± 23.2

72.3 ± 18.9

0.387

75.3 ± 24.7

76.5 ± 20.3

0.554

 Mortality within 6 months, n (%)

15 (78.9)

19 (15.7)

< 0.001

9 (40.9)

14 (9.2)

< 0.001

  1. AECOPD acute exacerbations of chronic obstructive pulmonary disease, BMI body mass index, CAP community-acquired pneumonia, CAT Chronic obstructive pulmonary disease assessment test, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease, mMRC modified Medical Research Council, n number, py pack-years, SD standard deviation, y years old
  2. amMRC dyspnea scale consists in five statements that describe almost the entire range of dyspnea from none (grade 0) to almost complete incapacity (grade 4)